Interstitial Lung Diseases

Interstitial lung diseases happen when the lungs are scarred. This health condition makes it difficult for the body to get enough oxygen.

Programs + Services

Interstitial Lung Disease Treatment at Tufts MC

Tufts Medical Center in Boston is proud to offer expert care for patients with interstitial lung diseases.
More information about programs and services

Interstitial Lung Disease

Tufts Medical Center's Interstitial Lung Disease Treatment Program provides advanced diagnosis options that help determine treatment for this disease
More information about programs and services

Doctors + Care Team

Kedar S. Deshpande, MD, FCCP
Request Appointment for Kedar S. Deshpande, MD, FCCP

Kedar S. Deshpande, MD, FCCP

Accepting New Patients

Title(s): Pulmonologist, Intensivist
Department(s): Pulmonary, Pulmonary Critical Care
Appt. Phone: 508-383-1525
Fax #: 508-383-1570

COVID, Long COVID, Asthma, COPD, Pulmonary hypertension, Interstitial Lung Disease, Sarcoidosis, Shortness of Breath, Lung Cancer

View Full Profile for Kedar S. Deshpande, MD, FCCP
Greg L. Schumaker, MD
Request Appointment for Greg L. Schumaker, MD

Greg L. Schumaker, MD

Accepting New Patients

Title(s): Medical Director, Lowell General Hospital ICU; Section Chief of Critical Care, Lowell General Hospital; Director, Rapid Response Team; Adult Sleep Medicine Attending; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, Pulmonary, Critical Care and Sleep Medicine
Appt. Phone: 617-636-6377
Fax #: 617-636-1649

Pulmonary diseases, critical care medicine, adult sleep medicine

View Full Profile for Greg L. Schumaker, MD

Research + Clinical Trials

A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

This is a Phase 2 study investigating safety and tolerability of Inhaled Treprostinil in participants with Pulmonary Hypertension associated with Interstitial Lung Disease.
More information about research and clinical trials

A Long-Term Extension, Multi-Center Safety Study of AV-101 in Subjects With Pulmonary Arterial Hypertension (PAH) Who Have Completed Study AV-101-002 (IMPAHCT-FUL)

This is a long-term extension (LTE) follow up study where recruitment of subjects will continue as the parent study (AV-101-002) progresses from Phase 2b to Phase 3. Subjects who were on placebo in Phase 2b and the Intermediate Part of the study who enroll in the LTE study will be re-randomized to one of the 3 active AV-101 doses until such time as the optimal dose has been selected. Once the optimal dose of AV-101 has been selected, all subjects will be transitioned to the optimal dose while they continue in the LTE, and subjects completing the Intermediate Part or parent study Phase 3 will enroll into the LTE study at the optimal dose.
More information about research and clinical trials